Peijia MedicalPEJMF 74 PS Ratio is 9.18 as of Jul. 04, 2026, which is 52% below its 10-year median of 19.16. GuruFocus rates PEJMF with a GF Score™ of 74/100 and a GF Value™ of $2.57. The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Peijia Medical ranks worse than 57.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Peijia Medical's share price is $1.3867.
Peijia Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15. Hence, Peijia Medical's PS Ratio for today is 9.18.
The historical rank and industry rank for Peijia Medical's PS Ratio or its related term are showing as below:
PEJMF'
s PS Ratio Range Over the Past 10 Years
Min: 3.18 Med: 19.16 Max: 1035.29
Current: 3.67
During the past 8 years, Peijia Medical's highest PS Ratio was 1035.29. The lowest was 3.18. And the median was 19.16.
PEJMF's PS Ratio is ranked worse than 57.89% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs PEJMF: 3.67
Peijia Medical Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Peijia Medical was 20.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 41.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 62.80% per year.
During the past 8 years, Peijia Medical's highest 3-Year average Revenue per Share Growth Rate was 130.40% per year. The lowest was 41.70% per year. And the median was 75.35% per year.
Back to Basics: PS Ratio
Peijia Medical (OTCPK:PEJMF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Peijia Medical PS Ratio Related Terms
Peijia Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Peijia Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Peijia Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peijia Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Peijia Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Peijia Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Peijia Medical's Share Price of today is $1.3867.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Peijia Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Peijia Medical (PEJMF) has a PS Ratio of 9.18 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Peijia Medical and its competitors. This is 52% below median its historical median of 19.16. Over the past decade, Peijia Medical's PS Ratio has ranged from 3.18 to 1,035.29. According to the industry distribution chart, Peijia Medical ranks #466 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 57.9%.
Is Peijia Medical's PS Ratio too high?
Peijia Medical's current PS Ratio of 9.18 is 52% below median its 10-year median of 19.16. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 1,035.29. The Medical Devices & Instruments industry median PS Ratio is 2.94. Peijia Medical's value of 9.18 is 212.2% above this industry median. Based on the distribution chart, Peijia Medical ranks #466 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Peijia Medical has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Peijia Medical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Peijia Medical ranks #466 out of 805 companies for PS Ratio. This places Peijia Medical in the lower half of its industry. The industry median PS Ratio is 2.94. Peijia Medical's value of 9.18 is 212.2% above this benchmark. Historically, Peijia Medical's own PS Ratio has ranged from 3.18 to 1,035.29 over the past decade. While the company's 10-year median is 19.16 vs. the industry median of 2.94, Peijia Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peijia Medical's current PS Ratio of 9.18 is 212.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Peijia Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peijia Medical's current PS Ratio is 9.18, which is 52% below median its own 10-year median of 19.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peijia Medical stock overvalued right now?
Peijia Medical (PEJMF) has a current PS Ratio of 9.18. The stock's GF Value™ is $2.57, compared to a current price of $1.39 — trading 46% below its estimated fair value. The current PS Ratio is 9.18, which is 52% below median its 10-year median of 19.16 and 212.2% above the Medical Devices & Instruments industry median of 2.94. Peijia Medical's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Peijia Medical (PEJMF), the current PS Ratio is 9.18 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peijia Medical (PEJMF) Overvalued in 2026?
Based on GuruFocus' analysis, Peijia Medical stock appears to be undervalued.
The current stock price of $1.39 is trading 46% below its estimated GF Value™ of $2.57.
Key valuation signals for PEJMF:
PS Ratio: 9.18 (52% below median its 10-year median of 19.16)
GF Value™: $2.57 vs. price of $1.39 (46% below fair value)
Industry Position: 212.2% above the Medical Devices & Instruments median (#466 of 805)
No single metric tells the full story. See the PEJMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peijia Medical Ltdis a provider of inventive medical products and solutions. It focuses on the high-growth interventional procedural medical device market in China. Its products and product candidates target large, fast-growing and under-penetrated markets with high entry barriers, including the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market. The Company's product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates spanning three key business segments: Transcatheter Valve Therapeutic Business, Future Technology Business and Neurointerventional Business.
74GF Score
Get the complete analysis for PEJMF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEJMF has been successfully added to your 
